In all, 22 African-American males undergoing radical prostatectomy for prostate adenocarcinoma had serum drawn for tPSA, cPSA, and total protein concentrations prior to, during, and after operation to determine the respective elimination rates. African-American cPSA was found to fit best a simple first-order exponential elimination kinetic, with a half-life of 44.6 h. fPSA followed a two-compartment elimination with an a-phase elimination of 0.50 h and a b-phase half-life of 4.2 h. Our results suggest higher rates of elimination for both cPSA and fPSA in an African-American male population with respect to Caucasians and may account for differences in PSA values between races.
Introduction
Measurement of serum prostate-specific antigen (PSA) has been the single most important advancement in the detection of early stage prostate cancer (CaP) in the past 15 y. Since Stamey's proposal for PSA to be used over other tumor markers, 1 the incidence of CaP has risen much more dramatically than the mortality rate. 2 Based on the Cancer Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute, 3 researchers realized that African-American males had a much higher incidence and mortality from prostate cancer than any other ethnic group. While AfricanAmerican males had a 31% higher detection of prostatic adenocarcinoma than Caucasian males, their mortality rate was an astonishing 117% higher. [2] [3] [4] [5] Investigators then began to look for answers to explain these disparate numbers. A number of studies have found that PSA levels in African-American males both with and without cancer are higher than their Caucasian counterparts. 4, [6] [7] [8] [9] [10] [11] [12] This has led to theories questioning whether the biology of prostate cancer in AfricanAmericans is the same as for Caucasians. AfricanAmerican males may have a higher tumor burden at diagnosis, 6 ,8 a higher histologic grade, 2, 6 and more seminal vesicle involvement. 7 While these facts could be attributable to socioeconomic factors unique to the United States, leading to a delay in diagnosis, 6 ,13 other clues exist suggesting otherwise. Young African-American men have been shown to have higher average testosterone levels. 6 The androgen receptor gene in African-American men may have a lower number of CAG repeats, which has been correlated with a higher risk of cancer of the prostate. 6 Montie and Pienta 13 have proffered an alternate model of carcinogenesis in African-American males. Based on the finding of increased PIN in African-American males as early as the age of 40 y, 14 higher grade tumors may develop earlier. In the setting of an altered hormonal milieu, these cancers could progress faster and present at a higher stage.
In this study, we sought to examine the behavior of PSA and its component fractions, complexed (cPSA) and free (fPSA), in African-American males. We reasoned that differences in the metabolism or elimination of PSA isoforms could contribute to the higher PSA values found among African-American men. Moreover, the rate of production of PSA may be inferred by the rate of elimination, which may give further insight into the activity of prostate cancer in African-American males. At the very least, discrepancies in PSA decay may affect treatment algorithms previously validated for Caucasian men only.
Methods
Informed consent to participate in this institutional review board-approved study was obtained from 35 consecutive men undergoing radical retropubic prostatectomy for localized adenocarcinoma of the prostate between 1999 and 2001. Blood samples were drawn at the beginning of the surgery (prior to Foley catheter insertion) and again immediately after the prostate gland was removed from the patient. This second blood draw was taken to be time zero (t 0 ) for purposes of kinetics modeling. Samples were then taken postoperatively at 1, 2, 4, 6, 12, 24, 48, and 72 h.
All blood samples were collected in EDTA-prepared tubes and centrifuged to separate the serum. The EDTA serum was then immediately frozen at À801C and thawed just before analysis. For each sample, cPSA was measured with the Bayer Immuno 1 TM cPSA assay (Bayer Corp., Tarrytown, NY, USA), a commercially available monoclonal assay. The assay detects PSA complexed to several protease inhibitors by using an excess of antibody to fPSA, rendering it unavailable for reaction in the cPSA assay. 15 tPSA was also measured via the Bayer Immuno 1 technique. fPSA was then calculated as the difference between tPSA and cPSA, based on prior work validating that cPSA plus fPSA was within 5% of the measured tPSA. 15 Determination of the serum protein concentration at each blood draw was also performed.
Three models of pharmacokinetic elimination were tested for both cPSA and fPSA using a mathematical modeling program, MLAB (Civilized Software, Bethesda, MD, USA). Curve fitting to the data was performed by the Marquardt-Levenberg method in MLAB. For the following examples, PSA(t) represents the cPSA or fPSA concentration at time t; P 0 represents the initial PSA concentration; m, k, a, and b are the rate constants to be solved; and A, B, and C are constants.
The simplest model of elimination of a substance from the blood stream is by a linear relationship, where a constant amount of a substance is eliminated per unit time. Equation (1) depicts this situation below:
Next, a simple first-order exponential elimination was evaluated, of the form
In this model, a constant fraction of a substance is eliminated per unit time. The amount of time necessary for one-half of the substance to be cleared from the circulation is expressed as the half-life (t 1/2 ), calculated as the natural logarithm of two divided by the rate constant, k. Often in the body, however, a substance must first equilibrate between the vascular space and some other volume of distribution, such as the interstitial space or the intracellular space. This two-compartment model can be constructed mathematically as a combination of two individual exponential functions, as follows:
The first term in the equation represents the initial equilibration and the second term represents the eventual clearance of the substance from the serum. A halflife can then be calculated for each of these phases of elimination. Each patient was individually processed through each model for both cPSA and fPSA, with objective 'tightness of fit' estimated by the determination coefficient, R 2 . Also, a graphical depiction of the data and each function generated was visually inspected to ensure correct correlation. Statistical analyses were then performed on the resultant rate coefficients and calculated half-lives to determine trends in PSA elimination based on preoperative PSA level, pathologic stage, and grade.
Additionally, an attempt was made to correct for the hemodilutional effects of surgery, as previous authors have suggested that the early phase of PSA elimination is influenced by the fluid shifts inherent in major surgery. 16 If one assumes a constant intravascular volume, a drop in the serum protein concentration postoperatively could reflect dilutional effects, and the true concentration of other blood-borne substances would be in effect higher. While the actual blood volume undoubtedly does fluctuate, this simple assumption allows us to construct a model relating relative hemodilution to the PSA concentration. Mathematically, this could be expressed as below:
where [prot] init is the preoperative total serum protein value, and [prot] t is the measured protein at the given time point. cPSA * and fPSA * were therefore calculated as above for each patient at each time point and subjected to the same models as described above.
Results
Of the 35 patients enrolled, 22 were included in this study. Two patients were excluded due to Caucasian race, one patient was excluded due to preoperative LHRH-agonist therapy, and 10 patients because of insufficient blood sample collection. Patient demographics are presented in Table 1 . The average patient was 60.3 y old with a cPSA of 7.46 ng/ml and a fPSA level at 2.01 ng/ml. In all, 16 had pathologically organconfined disease. Only six patients had positive margins, and one patient had a single lymph node involved with tumor. No patient was found to have detectable PSA at the 30-day postoperative visit, suggesting metabolically insignificant residual disease. Average blood loss was less than 1 l, with only two patients requiring the transfusion of blood products.
Of the 22 patients, 19 experienced a rapid rise in fPSA from the preoperative level to time zero, specimen excision. Only 13 saw an elevation of the cPSA level from baseline, with three of these patients not reaching a peak cPSA concentration until 4 or 6 h postexcision. For the following models, tightness of fit was arbitrarily defined as an R 2 determination coefficient greater than 0.700 and visual confirmation of appropriate fit on a graphical representation of the resultant function.
Linear kinetics
Of the 22 patients, 17 showed a good fit for cPSA to a linear model of elimination. The average slope of decay was 0.076 ng/ml/h. Using cPSA * , the cPSA value adjusted for protein loss by Equation (4) 
Two-compartment first-order kinetics
No model could be fashioned to fit cPSA or cPSA * to a two-compartment model. fPSA, however, displayed exceptional curve-fitting to this kinetic. Of the 22, 17 had R 2 values greater than 0.900 (an additional patient fit well with R 2 ¼ 0.77). The average early phase, or a-phase, elimination showed a half-life of 0.50 h, with a late, or bphase half-life of 4.20 h. Visually, the curve fitting for the two-compartment model was far superior to the simple first-order model.
The same number of patients fit well to the fPSA * model (18 out of 22), but in 13 out of 22 the R 2 values were higher, supporting better curve-fitting when accounting for hemodilution. For this model, the a-phase half-life was 0.87 h with a b-phase elimination of 5.51 h. Figure 1 shows a representative patient's plotting of cPSA and fPSA data to the above models. The illustration also shows curve-fitting to cPSA * and fPSA * data for comparison.
Statistical analyses
Next, we examined whether clinical or pathologic parameters influenced the observed elimination rates.
Preoperative tPSA (less than 10 ng/ml), pathologic stage (less than T2c), Gleason sum (2-4, 5-6, or 7-10), or margin status (negative or positive) were all evaluated for statistically significant differences in rates of elimination. The data were found not to be normally distributed by the Shapiro-Wilk test; therefore, nonparametric tests for the equality of medians were used (either the Wilcoxon or Kruskal-Wallis test, as appropriate).
Only negative margin status in the b-phase elimination of fPSA was determined to have a statistically significant lower half-life (3.1 h vs 27.5 h for positive margins, P ¼ 0.006). Patients with negative margins had an average cPSA half-life of 40.3 hours, while those with positive margins averaged 58.2 h, but this was not statistically significant (P ¼ 0.27). Preoperative tPSA, Gleason grade, and pathologic stage were not predictive of faster rates of elimination for complexed or free PSA (data not shown).
Discussion
PSA is a neutral serine protease produced almost exclusively by prostatic epithelial cells. The majority of PSA in serum exists as a complex with various protease inhibitors, the most important of which is a-1-antichymotrypsin (ACT). 15 The Bayer Immuno 1 Assay (Tarrytown, NY, USA) for PSA uses the MM1 monoclonal antibody to detect both free and complexed forms of PSA. With the addition of an excess of the ME2 antibody, which binds the free PSA aE-epitope, the free portion of PSA is eliminated from reaction with MM1, and the resulting measurement is representative of the cPSA fraction. 15 While fPSA has a molecular weight of approximately 37 kDa, the various PSA complexes have molecular weights between 78 kDa (for PSA-a2-macroglobulin) to 100 kDa (PSA-ACT). 17 This would suggest either that the body eliminates these substances by different mechanisms or that the free portion must bind to a protease inhibitor before metabolism.
Various authors have suggested that fPSA, of similar weight to albumin, is excreted by the kidney. [17] [18] [19] cPSA, however, is too large for glomerular filtration; in fact, Semjonow et al, 20 failed to detect total PSA in the urine following radical prostatectomy. Receptors for serpinenzyme complexes have been discovered on the surface of hepatocytes, 21, 22 suggesting hepatic metabolism of PSA complexes. Agha et al, 17 measured a significant concentration drop of total PSA through the hepatic circulation, supporting this theory.
Few studies exist, however, examining strictly the elimination rate of cPSA. Stephan et al, 23, 24 found very stable levels of cPSA for the first 6 h after surgery, followed by a steady decline. Therefore, these authors were unable to calculate an elimination rate with a twocompartment model. Likewise, Lilja et al, 19 commented that cPSA elimination seemed to follow a linear, zeroorder kinetic, but were unable to calculate a value because of insufficient sample size. Bjork et al, 25 studied 10 patients and found the linear elimination to be 0.8 ng/ ml/day.
In African-American men, we found that cPSA best fits an exponential model. However, we did achieve a reasonable fit for 17 of our 22 patients to a zero-order cPSA and fPSA elimination BJ Martin et al model. The average elimination rate was 0.076 ng/ml/h, or 1.8 ng/ml/day, much greater than that published by Bjork.
For comparison of our cPSA elimination rates, then, we must turn to prior studies with tPSA. Table 2 summarizes these reports. Presumably, these studies were performed primarily on Caucasian patients, and there is disagreement on the best model for elimination. For those supporting a first-order elimination, half-lives range from 45.6 to 75.6 h. 20, 26, 27 For those espousing a two-compartment model, the b-phase half-lives range from 33 to 182 h. 1, 16, 24, 26, 28 It is possible that the twocompartment models with tPSA truly reflect an a-phase elimination of fPSA and the b-phase represents the firstorder elimination of cPSA.
Our finding of an African-American male cPSA elimination half-life of 44.6 h falls within the lower range of these studies. This may suggest that African-American male elimination of cPSA is faster than for Caucasian men.
Multiple studies do exist, however, looking at the elimination of fPSA from serum (see Table 3 ). There is universal agreement that fPSA follows a two-compartment model of elimination, with the a-phase ranging from 0.57 to 1.8 h, and the b-phase half-life lasting 6.0-22 h. 16, 18, 19, 24, 25, 28 Our results agree with this two-phase cPSA and fPSA elimination BJ Martin et al pattern of elimination, but our calculated half-lives appear to be much shorter than those previously published, with an initial half-life of 0.50 h and a later half-life of 4.20 h. Again, this suggests African-American men eliminate fPSA faster than Caucasian men. There are currently three theories to explain the two-compartment model of fPSA elimination. The first theory asserts that fPSA is rapidly excreted by the kidneys, consistent with its low molecular weight, which accounts for its faster, initial phase elimination. 18, 19, 28 A second theory states that fPSA forms complexes in the serum with protease-inhibitors, thus rendering it undetectable by fPSA assay methods but not truly removing it from circulation. 23, 29 Stephan et al, 24 lent support to this theory by demonstrating constant levels of cPSA while fPSA levels dropped in the immediate postoperative period. The final theory states that the initial phase merely reflects perioperative hemodynamic changes and fluid shifts, so that the true elimination of fPSA does not manifest until the prolonged, later bphase. 1, 16, 25 Brandle et al, 16 found that serum protein and albumin concentrations demonstrated statistically similar rates of decay to fPSA and tPSA in the immediate postoperative period, suggesting that the a-phase was an artifact.
To test this final theory, we attempted to account for changes in PSA concentrations commensurate with changes in the serum total protein concentration. We used a simple mathematical transformation (Equation (4)) based on the idea that if serum protein concentrations dropped, this signified hemodilution, and the true PSA concentrations would be higher were it not for this effect. Support for this notion comes from the fact that the intraoperative fluid replacement was much greater than the estimated blood loss for all patients (see Table 1 ). For the majority of patients, serum protein values fell immediately after the operation but returned to baseline levels by 6-48 h postoperation. Therefore, our transformation of PSA values had the maximum effect during the initial a-phase in question.
These mathematically transformed PSA values, called cPSA * and fPSA * , actually demonstrated superior curvefitting for all models of elimination (see Figure 1) . The calculated half-life for cPSA * was 34.9 h. fPSA * displayed an initial half-life of 0.87 h, and a b-phase elimination half-life of 5.5 h. As before, these values are well below previously reported elimination rates of tPSA or fPSA in Caucasian men. Additionally, this crude manipulation of the concentrations suggests that while perioperative fluid changes may affect our observed elimination of fPSA, it cannot be responsible for the entire early phase seen. Also, if postoperative factors were the major influence on cPSA or fPSA elimination in the first few hours, then both would follow a two-compartment model, which was not seen in our study.
From all of the above results, the rate of elimination of both cPSA and fPSA in African-American men appears to be faster than previously published rates for Caucasian men. At steady-state conditions, the rate of PSA elimination from the circulation should equal the rate of PSA entrance into the circulation. Increased amounts of PSA in the circulation would result from either increased rates of PSA production by the carcinoma or faster rates of diffusion into the vascular space by PSA. Therefore, our elimination rates suggest either that both fPSA and cPSA production in African-American men exceed that of Caucasian men, or that there is greater communication between the tumor cells and the blood stream in AfricanAmericans. This could lend further support to the theory that prostate cancer in African-American men is biologically distinct from that of Caucasian men.
We next explored whether the tumor pathology exerted an influence on the elimination half-lives for cPSA and fPSA. In general, no statistically significant difference was seen based on tPSA, Gleason sum, pathologic stage, or margin status. Only the delayed excretion phase of fPSA showed a shorter half-life in margin-negative patients (3.1 vs 27.5 h). Semjonow et al, 20 however, found longer half-lives for tPSA in patients shown to have a biochemical failure at follow-up. Six of our patients had positive margins at surgery, but none had detectable PSA levels at his 1 month postoperative visit. Longer follow-up for our patients will be necessary to prove that cancer persistence or recurrence was not responsible for the lengthened half-lives.
If those patients most likely to have biochemical failure because of microscopic tumor foci persistence after surgery, that is, those with positive margin status, are excluded from the analysis, the elimination half-lives for African-American males become even lower. The average cPSA elimination half-life for margin-negative patients was 40.3 h. For fPSA, the a-phase half-life was 0.41 h with the delayed b-half-life only 3.1 h. Again, these values suggest higher baseline free-and complexed-PSA production rates or vascular diffusion rates in African-American males at steady state.
Conclusions
The elimination of cPSA from serum in African-American men follows a simple first-order kinetic with a halflife of 44.6 h. Considering only patients with negative margins, this half-life falls to 40.3 h, while adjusting for hemodilutional effects of surgery lowers the elimination half-life further to 34.9 h. The elimination of fPSA follows a two-compartment model, with an initial a-phase half-life of 0.50 h and a later b-phase half-life of 4.2 h. Patients with negative operative margins showed faster elimination rates of 0.41 h for the a-phase and 3.1 h for the b-phase. These values may be increased slightly to 0.87 and 5.5 h, respectively, if hemodynamic factors are included. These are the first reports of cPSA and fPSA elimination in African-Americans. Further work is needed in the pharmacokinetics of cPSA and fPSA in both Caucasian and African-American men to determine 
